Literature DB >> 8643762

Verbal fluency in schizophrenia: relationship with executive function, semantic memory and clinical alogia.

E M Joyce1, S L Collinson, P Crichton.   

Abstract

To examine whether poor verbal fluency in schizophrenia represents a degraded semantic store or inefficient access to a normal semantic store, 25 normal volunteers and 50 DSM-III-R schizophrenic patients, matched for age, sex and IQ, were recruited. Although schizophrenic patients were impaired on both letter and category fluency, they showed a normal pattern of output in that category was superior to letter fluency, and an improvement in category fluency when a cueing technique was employed (Randolph et al. 1993). These results resemble those found in disorders of frontostriatal systems (Parkinson's and Huntington's disease) and suggest that poor verbal fluency in schizophrenia is because of inefficient access to semantic store. A measure of improvement with cueing was directly related to performance on the Stroop executive task. Of all symptom measures derived from SANS and Manchester Scales, only alogia was related to verbal fluency in that superior improvement correlated inversely with the degree of alogia. It is suggested that both alogia and poor verbal fluency are mediated by the same underlying cognitive abnormality that reflects frontostriatal dysfunction.

Entities:  

Mesh:

Year:  1996        PMID: 8643762     DOI: 10.1017/s0033291700033705

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  24 in total

1.  The current conceptualization of negative symptoms in schizophrenia.

Authors:  Stephen R Marder; Silvana Galderisi
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

2.  Frontal lobe alterations in schizophrenia: neuroimaging and neuropsychological findings.

Authors:  Juan Carlos Sanz de la Torre; Maite Barrios; Carme Junqué
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-22       Impact factor: 5.270

3.  Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity.

Authors:  Sunny J Dutra; Luke E Stoeckel; Sara V Carlini; Diego A Pizzagalli; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2011-06-22       Impact factor: 4.530

4.  Preliminary evidence for impaired rapid verb generation in schizophrenia.

Authors:  Steven Paul Woods; Michael Weinborn; Carolina Posada; Joy O'Grady
Journal:  Brain Lang       Date:  2006-12-11       Impact factor: 2.381

5.  Cognitive functioning and negative symptoms in first episode schizophrenia: different patterns of correlates.

Authors:  José Manuel Rodríguez-Sánchez; Benedicto Crespo-Facorro; César González-Blanch; Rocío Pérez-Iglesias; Mario Alvarez-Jiménez; Obdulia Martínez; José Luis Vázquez-Barquero
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

6.  Grammatical processing in schizophrenia: evidence from morphology.

Authors:  Matthew Walenski; Thomas W Weickert; Christopher J Maloof; Michael T Ullman
Journal:  Neuropsychologia       Date:  2010-01       Impact factor: 3.139

7.  Verbal fluency in anorexia nervosa.

Authors:  Kristin Stedal; Nils Inge Landrø; Bryan Lask
Journal:  Eat Weight Disord       Date:  2013-04-11       Impact factor: 4.652

8.  Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study.

Authors:  Gail A Laughlin; Donna Kritz-Silverstein; Elizabeth Barrett-Connor
Journal:  Clin Endocrinol (Oxf)       Date:  2009-03-30       Impact factor: 3.478

9.  Verbal fluency, semantics, context and symptom complexes in schizophrenia.

Authors:  Adam P Vogel; Helen J Chenery; Catriona M Dart; Binh Doan; Mildred Tan; David A Copland
Journal:  J Psycholinguist Res       Date:  2009-03-04

10.  Deriving semantic structure from category fluency: clustering techniques and their pitfalls.

Authors:  Wouter Voorspoels; Gert Storms; Julia Longenecker; Steven Verheyen; Daniel R Weinberger; Brita Elvevåg
Journal:  Cortex       Date:  2013-10-10       Impact factor: 4.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.